Log in to search using one of your social media accounts:

 

ALung closes $36m Series C

Artificial lung-like device developer ALung Technologies said today it closed a $36 million Series C financing round, with funds slated to support a US pivotal trial of its Hemolung respiratory assist system as it pursues FDA approval. The Pittsburgh, Penn.-based company is developing the Hemolung device, an extracorporeal carbon dioxide removal system that works by removing carbon dioxide and delivering oxygen directly to a patient’s blood via a small catheter inserted into the jugular or femoral vein. The funding round was led by Royal Philips (NYSE:PHG) and UPMC and joined by Abiomed (NSDQ:ABMD), The Accelerator Fund, Allos Ventures, Birchmere Ventures, Blue Tree Ventures and Riverfront Ventures. “Since 2013, hundreds of patients with acute respiratory failure have been successfully treated with the Hemolung RAS outside of the United States. With this new financing, we will be able to conduct our US-based clinical trial, an important step towards obtaining FDA approval and making our device available to patients in the United States. We are grateful to Philips, UPMC, and our many other investors for their commitment to ALung and the numerous patients who stand to benefit from our technology,” ALung CEO &chair Peter DeComo said in a press release. As part of the funding round, Philips patient care &monitoring systems chief medical officer Dr. Adam Seiver and UPMC’s Jeanne Cunicelli will join ALung’s board of directors, the com...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News Respiratory Abiomed Inc. ALung Technologies Inc. Royal Philips Source Type: news

Related Links:

650,000 renal, hepatic, and cardiothoracic (heart and/or lung) transplants have been performed in the U.S. since 1988, with UNOS reporting a 20% increase in transplants between 2012 through 2016. The immunosuppression vital to maintaining graft survival comes with a 65-200X greater frequency of SCC compared to the non-transplant population. These SCC exhibit more aggressive behavior, withincreased morbidity and mortality. The aim of this study was to investigate the impact of rejection on the incidence and presentation of SCC.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Clinical Research: Epidemiology of Skin Diseases Source Type: research
A LITTLE girl born without a diaphragm has become the first person in Britain to have one built by medics using pig skin. Eve Phillipson, two, had endured two failed operations to rebuild the layer of muscle separating the lungs and the stomach when surgeons made a third and final attempt.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Conclusion: IT following lung and liver transplantation, with injection of islets into a transplanted organ, is feasible. It improves C-peptide secretion, decreases insulin needs, and lowers HbA1c.Horm Res Paediatr
Source: Hormone Research in Paediatrics - Category: Endocrinology Source Type: research
Organs donated from people infected with hepatitis C can be safely transplanted, and any transmission of the virus can be treated with antiretrovirals, new research shows.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Transplantation News Source Type: news
Conditions:   Idiopathic Pulmonary Fibrosis;   Emphysema or COPD Interventions:   Biological: CD3/CD19 negative hematopoietic stem cells;   Drug: Rituximab;   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Thiotepa;   Drug: G-CSF;   Drug: Hydroxyurea Sponsor:   Paul Szabolcs Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Lung Transplant Rejection Intervention:   Device: photopheresis Sponsors:   Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico;   Italian Cystic Fibrosis Research Foundation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Idiopathic Pulmonary Fibrosis;   Emphysema or COPD Interventions:   Biological: CD3/CD19 negative hematopoietic stem cells;   Drug: Rituximab;   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Thiotepa;   Drug: G-CSF;   Drug: Hydroxyurea Sponsor:   Paul Szabolcs Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Lung Transplant Rejection Intervention:   Device: photopheresis Sponsors:   Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico;   Italian Cystic Fibrosis Research Foundation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Scientists at the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital have uncovered a novel, two-agent immunotherapy combination that worked surprisingly well in animal models with malignant mesothelioma. The discovery has sparked new optimism for immunotherapy, which has struggled to provide consistently positive results with aggressive cancers such as mesothelioma. “This is the beginning of a new story of hope, a new combination of immunotherapy,” Dr. Mark Poznansky, director of the VIC and associate professor at Harvard Medical School, told Asbestos.com. “It worked quite well in a...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Source Type: research
More News: Clinical Trials | Funding | Hospitals | Lung Transplant | Respiratory Medicine | Science